Adaptimmune Therapeutics PLC 10-Q filing
Filed 2025-08-13 · Report date 2025-06-30 · 2025
Filing metadata
- Accession number
- 0001558370-25-011307
- Form type
- 10-Q
- CIK
- 0001621227
- Primary document
- https://www.sec.gov/Archives/edgar/data/1621227/000155837025011307/adap-20250630x10q.htm
Extracted primary information
This filing includes deterministic financial metrics extracted from public filing data for Adaptimmune Therapeutics PLC.
Reported financial metrics
| Metric | Current | Prior | Change |
|---|---|---|---|
| Revenue | $21.0M | - | - |
| Cost Of Revenue | $3.4M | - | - |
| Operating Income | $-76.0M | - | - |
| Net Income | $-77.9M | - | - |
| Eps Basic | -0.05 | - | - |
| Eps Diluted | -0.05 | - | - |
| Cash And Equivalents | $26.1M | - | - |
| Total Assets | $130.6M | - | - |
| Total Liabilities | $201.6M | - | - |
| Shareholders Equity | $-71.0M | - | - |
| Operating Cash Flow | $-101.4M | - | - |
| Capital Expenditures | $1.3M | - | - |